Brief: KOL Review Of Lumos's Interim Mid-Stage Data Supports Potential For New Oral Therapeutic For Moderate Idiopathic PGHD
12/12/2022 12:58
Dec 12 (Reuters) - Lumos Pharma Inc LUMO.O :
* KOL REVIEW OF LUMOS PHARMA’S INTERIM PHASE 2 DATA SUPPORTS
POTENTIAL FOR NEW ORAL THERAPEUTIC PARADIGM FOR MODERATE
IDIOPATHIC PGHD PATIENTS
Source text for Eikon: ID:nGNXc5swFf
Further company coverage: LUMO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lumos Pharma
See all newsLumos Pharma Inc expected to post a loss of 76 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Apple, Hershey, Dow
U.S. STOCKS ON THE MOVE-Magnite, Nvidia, Tesla
Lumos Pharma climbs on $38 mln go-private deal
Brief: Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures To Go Private Via A Tender Offer Of $4.25 Cash Per Share Plus Contingent Value Rights (Cvr)